Wave crashes again – this time on toxicity concerns
A run of bad news leaves investors questioning Wave Life Sciences’ ability to deliver on its promises.
Readouts approach for biggest Huntington’s hopes
Upcoming data from Roche/Ionis and Wave Life Sciences will be an important test of potentially disease-modifying candidates.
Novo sets up antisense challenge with Staten deal
Novo Nordisk’s first cardiovascular collaboration could lead to an antibody versus antisense showdown in dyslipidaemia.
Takeda forges another neuroscience deal as Abbvie dips a toe
Takeda's appetite for risk in early stage neuroscience could make it one to watch.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.